Vesugen Peptide: Lys-Glu-Asp Vascular Bioregulator Evidence and Limits
Vesugen peptide guide covering the Lys-Glu-Asp (KED) tripeptide bioregulator, proposed gene-expression and vascular mechanisms, the thin human evidence base and safety limits.
Vesugen is a synthetic tripeptide with the sequence Lys-Glu-Asp, usually abbreviated KED. It belongs to the family of "short peptide bioregulators" associated with Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It is marketed as a vascular bioregulator, meaning it is promoted for endothelial and cardiovascular support during aging.
That framing needs an immediate caveat. Vesugen is not an approved medicine in the United States or Europe. It is sold in Russia as a biologically active food supplement and elsewhere on the research-chemical market. Almost all published data come from a single research network, and the strongest evidence is in cell culture and rodents, not controlled human trials. So this is a compound with an interesting mechanistic story and a thin clinical record at the same time.
This guide is educational and not medical advice. Vesugen is research-only and unapproved. Nothing here is a protocol, a dose recommendation, or an endorsement of human use. For background on how these molecules are classified, see what peptides are and the peptide half-life guide.
Vesugen At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic tripeptide, Lys-Glu-Asp (KED), in the Khavinson short-peptide bioregulator family. |
| Proposed role | "Vascular" bioregulator promoted for endothelial and cardiovascular aging support. |
| Mechanism claim | Modulation of gene expression via direct DNA and histone interaction, not classical receptor agonism. |
| Approval status | Not FDA approved; a Russian food supplement; otherwise research-only. |
| Evidence type | Mostly in vitro and rodent work plus small uncontrolled human observations from one research network. |
| Main safety frame | Limited human safety data; risk profile is essentially uncharacterized by modern trial standards. |
The Proposed Mechanism
Most peptide drugs you read about act on a receptor. Khavinson short peptides are described differently. The central hypothesis from this research group is that ultrashort peptides of two to four residues can penetrate the cell nucleus, reach the nucleolus, and bind directly to DNA in gene promoter regions and to histone proteins. In that model the peptide is an epigenetic-style regulator that nudges transcription of specific genes, rather than a ligand that flips a single receptor.
For Vesugen specifically, the cardiovascular claims center on endothelial signaling. Review articles from the group propose that KED can influence expression of molecules involved in vascular aging and atherosclerosis, with endothelin-1, connexins, and sirtuin-1 frequently named. Independent vascular work has confirmed that these three molecules are dysregulated in human endothelial cells during atherosclerosis and restenosis, with endothelin-1 and connexin-37 elevated several fold; the open question is whether a Lys-Glu-Asp tripeptide meaningfully corrects that in living humans, which has not been demonstrated in controlled trials.
A 2021 systematic review of peptide regulation of gene expression, authored by the Khavinson group, lists KED among peptides that altered messenger RNA for senescence and apoptosis genes such as p16 and p21 and for neurogenesis genes such as NES and GAP43. That is the kind of finding that fuels the "longevity" positioning, but it is mechanistic cell-level data, not an outcome.
What The Evidence Actually Shows
It is worth separating the layers of evidence, because they are not equal.
The strongest layer is in vitro. Cell-culture studies report that KED at nanogram concentrations changed expression of senescence markers and neurogenesis genes and, in a hippocampal-neuron Alzheimer's disease model, increased the number of mature ("mushroom") dendritic spines by roughly 20 percent. These are plausible, reproducible-looking laboratory signals.
The next layer is rodent and review synthesis, which extends the gene-expression narrative to geroprotection and cardiovascular and neural function. This is where mechanism and marketing start to blur, because reviews from the same network tend to aggregate many small studies into broad capability claims.
The thinnest layer is human. The published human signal for KED is essentially a statement that oral application improved memory and attention in elderly people with functional central nervous system disorders, reported within the group's own articles, without the design transparency of a registered randomized controlled trial. There is no independent Western trial, no FDA or EMA review, and no robust pharmacokinetic dataset. That matters: a tripeptide this small is expected to be cleared from plasma within minutes, and no peer-reviewed human pharmacokinetic profile establishes how oral or injected KED would reach the tissues it is claimed to act on.
In short, the laboratory story is more developed than the human story, and the human story does not yet support efficacy claims.
A Note On The Bioregulator Family
Vesugen does not stand alone. It is one of several Khavinson "Cytogen" tripeptides and tetrapeptides, each marketed for a different tissue. The most famous relative is the pineal tetrapeptide Epitalon (Ala-Glu-Asp-Gly), which carries the same longevity framing and the same single-network evidence limitation. A useful, slightly uncomfortable detail is that the Lys-Glu-Asp sequence appears as the opening residues of other family peptides aimed at entirely different organs, which raises a fair question about how tissue-specific these short sequences can really be.
If you are evaluating Vesugen for vascular or longevity reasons, it is reasonable to compare its evidence quality against compounds in adjacent categories that have more transparent mechanistic and trial data, such as the mitochondrial peptides MOTS-c and SS-31 (elamipretide), or the senolytic-style construct FOXO4-DRI. None of those are approved either, but the contrast helps calibrate how much weight a single-network supplement-grade peptide should carry.
Safety
The honest safety statement for Vesugen is that its safety is largely uncharacterized by modern standards. Proponents describe it as well tolerated, and short peptides like this are generally low in acute toxicity in animal work. But "few reported problems" in small uncontrolled observations is not the same as a demonstrated safety profile, and most consumer-facing product is research-grade material of variable purity.
| Safety issue | Why it matters |
|---|---|
| No regulatory review | Not assessed by FDA or EMA; no approved label defines safe use, dosing, or contraindications. |
| Sparse human data | Reported tolerability comes from small, uncontrolled, single-network observations, not controlled trials. |
| Product quality | Research-chemical and supplement vials are not subject to pharmaceutical manufacturing oversight; purity, sterility, and identity vary. |
| Injection risk | Reconstituted research peptides carry the usual injection hazards: contamination, infection, and dosing error. |
| Unknown interactions | No formal drug-interaction, pregnancy, or long-term safety studies exist. |
| Mechanistic uncertainty | A compound claimed to alter gene expression has, in principle, effects that are hard to predict or monitor. |
The Russian product is generally sold as oral capsules, while the international research market sells lyophilized vials intended for reconstitution and subcutaneous injection. Neither form has the safety documentation expected of an approved drug.
How To Evaluate A Vesugen Claim
When you see a strong Vesugen claim, run it through a few filters.
First, ask where the data came from. If every citation traces back to one research network, that is a replication gap, not a conspiracy, but it should lower your confidence.
Second, separate mechanism from outcome. "Changed p16 messenger RNA in a dish" is a mechanism. "Reduced cardiovascular events in people" is an outcome. Vesugen marketing often presents the former as if it implied the latter.
Third, look for the trial. A real efficacy claim needs a randomized, controlled, independently reported human study. For Vesugen, that does not currently exist.
Fourth, check the regulatory status honestly. "Sold in Russia as a supplement" is not the same as "approved as a medicine."
Fifth, be skeptical of stacking logic. Family resemblance to other bioregulators or to better-studied peptides does not transfer their evidence to Vesugen.
Bottom Line
Vesugen, the Lys-Glu-Asp tripeptide, is a genuinely interesting research molecule with a coherent proposed mechanism: nuclear, gene-expression-level modulation of vascular and senescence pathways. The laboratory data showing changes in senescence and neurogenesis genes are real findings worth following.
But the gap between that mechanism and any proven human benefit is wide. The human evidence is minimal and comes almost entirely from one research network, there is no independent randomized trial, there is no regulatory approval, and there is no robust human pharmacokinetic or long-term safety dataset. Vesugen should be understood as a research-only, unapproved compound with promising in vitro signals and unestablished clinical value, not as a validated vascular or longevity therapy.
References
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053.
Khavinson VK, Linkova NS, Umnov RS. Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer's Disease. Bull Exp Biol Med. 2021.
Khavinson V, et al. Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease. Bull Exp Biol Med. 2017.
Ashapkin VV, Linkova NS, Khavinson VK, Vanyushin BF. Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease. Int J Mol Sci. 2022.
Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO. Expression of Signal Molecules in Culture of Human Endothelial Cells in Atherosclerosis and Restenosis. Bull Exp Biol Med. 2017.
Avolio F, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022;23(7):3607.
Lin'kova NS, et al. Effects of Lys-Glu-Trp peptide on cell-cell interactions and vascular endothelium proliferation under normal conditions and during atherosclerosis. Bull Exp Biol Med. 2014.
Khavinson VK. Peptide regulation of aging: 35-year research experience. Bull Exp Biol Med. 2009.
Anisimov VN, Khavinson VK, et al. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011.